VCYT - Veracyte Inc logo

Veracyte Inc

VCYT

Veracyte, Inc. is a molecular diagnostics company that develops genomic tests for cancer diagnosis, including the Afirma classifier for thyroid cancer, Decipher classifiers for prostate and bladder cancers, and the Percepta test for lung cancer.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$6,050today

Score Overview

1 Year
Score
Net Growth72.54%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth8.65%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.2
Net Growth251.51%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth155.97%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth465.08%
Net Trend70%
Net Income Consistency
Rev Growth8x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth6x
Net Trend62%
Net Income Consistency
Rev Growth25x
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Veracyte Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. VCYT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 46.04โ€”
1 Year2025-09-30
$ 34.3334.11%
5 Years2021-09-30
$ 46.45-0.88%
10 Years2016-09-30
$ 7.616x
All Time2013-10-30
$ 13.25247.47%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 561M$ 114M$ 485M
2025$ 517M$ 66M$ 412M
2024$ 445M$ 24M$ 289M
2023$ 361M-$ 74M$ 216M
2022$ 296M-$ 36M$ 178M
2021$ 219M-$ 75M$ 177M
2020$ 117M-$ 34M$ 349M
2019$ 120M-$ 12M$ 159M
2018$ 92M-$ 22M$ 77M
2017$ 71M-$ 31M$ 33M
2016$ 65M-$ 31M$ 59M
2015$ 49M-$ 33M$ 39M
2014$ 38M-$ 29M$ 35M
IPO2013$ 21M-$ 25M$ 71M
VCYT - Veracyte Inc logo

Veracyte Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 117M to $ 517M and net income went from -$ 34M to $ 66M. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 49M to $ 517M and net income went from -$ 33M to $ 66M. Revenue increased in 9 of those 10 years; net income in 7.

Veracyte Inc currently holds a 5-year HDB Score of 8.2 out of 10. How the HDB Score is calculated.

Membership

Explore VCYT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies